Recent Updates — VBIO

Valion Bio issued 4,717.73 shares of Series C Non-Voting Convertible Preferred Stock and warrants to purchase 2,524,343 common shares at an initial exercise price of $1.0092 per share. The aggregate transaction value is approximately $4.7 million, consisting of $1.5 million in cash proceeds and $3.2 million retained by purchasers to satisfy overdue cash true-up payments under the Series C Certificate of Designation. Additionally, Valion Bio issued 50 shares of Series B Preferred Stock and warrants for 1,539 common shares at $1.0092 per share for an aggregate purchase price of $50,000 in cash. These securities were sold under exemptions from registration pursuant to Section 4(a)(2) or Rule 506(b). Valion Bio is a biotechnology company focused on developing therapies.

Valion Bio, Inc. announced the completion of formulation work for a novel oral mucosal version of its investigational biologic Entolimod, utilizing Shear Kershman Laboratories’ proprietary BioViscid™ drug-delivery platform. This milestone establishes a potential second needle-free development pathway alongside the company's existing injectable program. The next phase will evaluate whether this formulation delivers measurable amounts of Entolimod into the bloodstream to determine systemic exposure and pharmacokinetic profiles. Valion estimates that if approved, the addressable opportunity for this oral formulation could be 10 to 40 times larger than the injectable program, targeting military, firefighter, and law enforcement personnel. Valion Bio, Inc. is a biotechnology company developing biologics for cytoprotection and immune modulation, primarily focused on Acute Radiation Syndrome.

Valion Bio, Inc. filed an amended 8-K to disclose the final certified voting results from its Special Meeting of Stockholders held on August 14, 2026. The company reported that stockholders approved Proposal No. 1, granting the Board discretionary authority to effect a reverse stock split of common shares at a ratio between 1-for-5 and 1-for-50 within twelve months. This proposal received 1,243,530 votes in favor against 697,127 opposed, with approximately 48.21% of outstanding common shares represented. Proposal No. 2 to adjourn the meeting was also approved but not utilized as the primary objective was achieved. Valion Bio, Inc. operates in the biotechnology industry.

Valion Bio, Inc. announced the termination of CEO Michael K. Handley effective August 16, 2026, and appointed CFO Lisa Wolf as Chief Operating Officer on the same date. The company entered into a letter agreement with 3i, LP to issue 1,500 shares of Series B Preferred Stock at $1,000 per share for an aggregate purchase price of $1,500,000, closing around August 17, 2026. Concurrently, a royalty agreement was executed granting investors 5% of gross revenue from subsidiary Velocity Bioworks, Inc. for ten years. At a Special Meeting on August 14, 2026, shareholders approved granting the Board discretionary authority to effect a reverse stock split at a ratio between 1-for-5 and 1-for-50 within twelve months. Valion Bio, Inc. operates in the biotechnology sector.